Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 3, 2010

BMS and Simcere Partner to Carry out First-In-Man Trials of Oncology Candidate in China

  • Bristol-Myers Squibb (BMS) granted Chinese firm Simcere Pharmaceutical rights to develop and commercialize the preclinical-stage oncology compound BMS-817378 in its home country. While BMS retains rights to develop its small molecule MET/VEGFR-2 inhibitor in all other markets worldwide, the initial focus will be on the initiation of first-in-human studies in China. The two firms will work together to hammer out the development plan for BMS-817378, which will initially be conducted by Simcere.

    The U.S. drugs giant claims that marrying the strengths of a Chinese pharmaceutical firm and global pharma company represents a completely new approach to the development of its early-stage pipeline.

    “This approach allows the partnership to leverage our well-recognized clinical and regulatory capabilities and our access to the vast patient pool in China,” remarks Peng Wang, Ph.D., Simcare CEO. “



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »